Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping.

Journal of the American Heart Association

Volumn 2, Issue 2, 2013, Pages

  Fontana, Pierre ^a   Cattaneo, Marco ^b   Combescure, Christophe ^b   Reny, Jean Luc ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; GENETIC POLYMORPHISM; GENETICS; GENOTYPING TECHNIQUE; HUMAN; METHODOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS; STANDARD; UTILIZATION REVIEW;

ARYL HYDROCARBON HYDROXYLASES; GENOTYPING TECHNIQUES; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIENOPYRIDINES; TICLOPIDINE;

EID: 84884363768     PISSN: None     EISSN: 20479980     Source Type: None    
DOI: 10.1161/JAHA.112.000131     Document Type: Article

References (0)